Evidence from recent systematic reviews.

<p>ADHD, attention deficit hyperactivity disorder; ALL, acute lymphoblastic leukaemia; EASI, the Eczema Area and Severity Index; FLG, filaggrin; HDM, house dust mites; IVIG, intravenous immunoglobulin; POEM, the Patient Oriented Eczema Measure; SCORAD, SCORing Atopic Dermatitis; TCS, topical corticosteroid; TGF, transforming growth factor, * between August 2010 and December 2011, ** updated on 16^th January 2013.</p><p>✓; probably effective based on systematic review evidence.</p><p>?; not clear, or limited evidence to recommendation.</p><p>X; unlikely to be effective based on systematic review evidence.</p

Geographic distribution of author’s institutions.

<p>Geographic distribution of author’s institutions.</p

Number of systematic reviews by category.

<p>Number of systematic reviews by category.</p

Numbers of published systematic reviews by year.

<p>Numbers of published systematic reviews by year.</p

Journals of publication.

<p>Journals of publication.</p

Systematic reviews in guidelines on atopic dermatitis published since 2007.

<p>AAAAI, American Academy of Allergy, Asthma and Immunology; AAP, American Academy of Pediatrics; BAD, British Association of Dermatologists; DDG, Deutschen Dermatologischen Gesellschaft [German Society of Dermatology]; DSSA, the Dermatological Society of South Africa; EADV, European Academy of Dermatology and Venereology; EDF, European Dermatology Forum; JAD, Japanese Dermatological Association; JSA, Japanese Society of Allergology; NICE, National Institute for Health and Clinical Excellence; SIGN, Scottish Intercollegiate Guidelines Network.</p>*<p>also on behalf of the European Task Force on Atopic Dermatitis (ETFAD), ^**also on behalf of the American College of Allergy, Asthma & Immunology (ACAAI) and the Joint Council of Allergy, Asthma & Immunology (JCAAI), ^***also on behalf of Royal College of General Practitioners (RCGP), ^****also on behalf of EADV, ETFAD, European Federation of Allergy (EFA), European Society of Paediatric Dermatology (ESPD), and Global Allergy and Asthma European Network (GA2LEN), ^†relevant articles to atopic eczema.</p

Odds of escalation of treatment and odds of using topical anti-inflammatory medication by change in bother score compared to the previous day.

<p>Odds of escalation of treatment and odds of using topical anti-inflammatory medication by change in bother score compared to the previous day.</p

Proportion of days in flare by mean POEM scores for AE severity.

<p>Proportion of days in flare by mean POEM scores for AE severity.</p

Baseline characteristics of included participants.

<p>¹ There was 1 missing value for SASSAD in Study A, and I missing value for POEM in both Study A and Study B.</p><p>Abbreviations: Standard Deviation (SD), Patient Oriented Eczema Measure (POEM), Six Area, Six Sign Atopic Dermatitis (SASSAD), Not applicable (N/A)</p><p>Baseline characteristics of included participants.</p

Resource use, cost and outcome in the combined PATCH trials.

<p>*Δ: Antibiotic – Placebo.</p>+<p>2010 costs; r_c refers to the discount rates applied to costs distributed over time.</p